Evidence map›Paper›PMID 30662637›Full record

ReviewAmerican journal of translational research2018

Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis.

Dongjun Dai, Shuting Han, Ling Li, Yan Guo, Yuping Wei, Hongchuan Jin, Xian Wang

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dongjun DaiDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University Hangzhou, China.
Shuting HanDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University Hangzhou, China.
Ling LiLaboratory of Cancer Biology, Key Lab of Biotherapy, Sir Run Run Shaw Hospital, Medical School of Zhejiang University Hangzhou, China.
Yan GuoLaboratory of Cancer Biology, Key Lab of Biotherapy, Sir Run Run Shaw Hospital, Medical School of Zhejiang University Hangzhou, China.
Yuping WeiDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University Hangzhou, China.
Hongchuan JinLaboratory of Cancer Biology, Key Lab of Biotherapy, Sir Run Run Shaw Hospital, Medical School of Zhejiang University Hangzhou, China.
Xian WangDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University Hangzhou, China.
Zhejiang University · CNSir Run Run Shaw Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen deprivation therapy (ADT) was an important management for metastatic prostate cancer. However, patients would finally progress to the metastatic castration-resistant prostate cancer (mCRPC) and lose sensitivity to ADT. In addition to lower testosterone level, ADT could cause anemia, which might impair the chemotherapy efficiency and worsen the outcomes of cancer patients. However, inconsistent results were found between anemia and mCRPC prognosis. Our study was the first systematic review to evaluate the influence of anemia in mCRPC prognosis. Thirteen studies with 6,484 samples were involved in this meta-analysis. We found anemia would worsen the Overall survival (OS) of mCRPC patients in both prognostic designed studies (HR = 1.55, 95% CI = 1.24-1.94) and retrospective designed studies (HR = 1.82, 95% CI = 1.52-2.18). Prognostic analyses also demonstrated that anemia associated with poor Progression free survival (PFS) (HR = 1.47, 95% CI = 1.22-1.75). In conclusion, we found that anemia was significantly associated with poor OS and PFS of mCRPC patients. Larger RCTs are needed for future study, especially for the evaluation of treatment value for anti-anemia in mCRPC.

Indexed as

androgen deprivation therapyanemiameta-analysismetastatic castration-resistant prostate cancerSystematic review

Identifiers

PMID30662637
PMCPMC6325522
OpenAlexW2991077165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.